A new once-daily pill is showing remarkable results in lowering “bad” cholesterol
Researchers are reporting a promising advance in the fight against cardiovascular disease. A new oral medication, called enlicitide decanoate, is being developed by Merck and is designed to block the PCSK9 protein. This protein plays a major role in controlling LDL, the form of cholesterol most associated with heart disease.
Phase-3 results, presented at the American Heart Association 2025 sessions, show that the pill can lower LDL levels by up to 59 percent. It is taken once a day and is being viewed as a potential breakthrough in cholesterol management.
Reducing LDL means less pressure on the cardiovascular system and a significantly lower risk of heart attack. More data will come as the studies continue, but the current results suggest a therapy that could reshape how high cholesterol is treated.
Eat Smart – Live Better

Comments
Post a Comment